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Effects of chronic treatment with angiotensin converting enzyme inhib-
itor or an angiotensin receptor antagonist in two-kidney, one-clip hyper-
tensive rats. The effects of chronic angiotensin II (Ang II) receptor
blockade (losartan) or converting enzyme inhibition (enalapril) on blood
pressure (BP), urinary albumin excretion (UaIbV), renal histology and the
hemodynamic and excretory function of the clipped and nonclipped
kidneys were studied in two-kidney, one-clip (2-K 1-C) rats. One day after
clipping the right renal artery, male Wistar rats were divided into three
groups receiving: (1) losartan, 20 mg/kg/day (N = 7), (2) enalapril, 20
mg/kg/day (N = 8), or (3) no treatment (controls, N = 9) for three weeks.
Both losartan and enalapril treatments maintained conscious BP at
comparably lowered levels compared to control animals (116 6 mm Hg
and 113 2 mm Hg vs. 188 11 mm Hg, respectively, P < 0.01).
Treatment also prevented the increase in UalhV, observed for the un-
treated group, three weeks after clipping (1.7 0.5 and 0.7 0.1 mg/24
hr vs. 17.8 7 mg/24 hr, respectively, P < 0.01). After three weeks of
treatment, acute study of renal function during pentobarbital anesthesia
revealed higher values of GFR and RPF and lowered vascular resistance
for nonclipped kidneys from the losartan and enalapril groups compared
to the corresponding kidneys from control animals. Despite the lower BP
of both treated groups, clipped kidney GFR and RPF were unchanged
compared to the control group. UIbV for nonclipped kidneys from
untreated rats was approximately 5- to 10-fold higher than in the
nonclipped kidneys from the treated groups. Histological evaluation
revealed evidence of early glomeruloselerosis in the nonclipped kidneys
from the untreated but not the treated groups, and decreased indices of
glomerular size and mesangial expansion in clipped kidneys for the treated
groups compared to the untreated group. These data support a primary
role for Ang 11 modulation of blood pressure and renal function in the
nonclipped kidney of the 2-K 1-C rat.
The contribution of the renin-angiotensin system (RAS) to the
development and maintenance phase of renovascular hyperten-
sion (RVH) has long been recognized. Earlier experiments with
pharmacological inhibitors of the RAS, such as angiotensin
converting enzyme inhibitors (CEI), prototypic peptide angioten-
sin II receptor antagonists or renin inhibitors demonstrated the
causal role of the RAS in the development and early maintenance
phases of hypertension in rat models of renal artery stenosis [1, 2].
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Guyton et al have proposed that the normal or nonstenotic kidney
should be protective for the development of hypertension in a
model of two-kidney single renal artery stenosis hypertension [3].
Several studies have demonstrated that acute blockade of the
RAS results in augmented renal hemodynamic and filtration
functions of the nonstenotic kidney during conditions when blood
pressure is decreased [1, 4, 5]. Consequently, it has been attractive
to postulate that effects of angiotensin II (Ang II) cause the
nonelipped kidney to participate in the hypertensive process by
forcing reabsorption of salt and water that would otherwise be
excreted in response to the hypertension-induced pressure diure-
sis. Although the acute and chronic blood pressure responses and
the effects of acute application of angiotensin converting enzyme
inhibitors (ACEI) on global renal function during the develop-
ment of hypertension have been described, the effects of chronic
interruption of the RAS on individual renal function for the
stenotic and nonstenotic kidneys during the developmental phase
of two-kidney, one-clip hypertension (2-K 1-C HT) have not, to
our knowledge, been reported. In models of established RVH,
acute and chronic administration of ACEI are associated with
deleterious effects on post-stenotic kidney structure or function [4,
6—8]. The probability that the use of ACEI in clinical practice is
likely to increase, especially in groups at a high risk for occult
renovascular disease, dictates that the effects of chronic RAS
blockade on renal structure and function especially in the post-
stenotic kidney in experimental renovascular disease merits fur-
ther investigation.
The effects of chronic administration of new specific angioten-
sin receptor antagonists on the function of each kidney have also
not been reported in this model. Losartan (DuP 753) is an orally
active AT1 Ang II receptor antagonist which lacks the partial
agonist properties of earlier receptor blocking agents [9, 10]. In
contrast to the suspected kinin potentiating effects of the convert-
ing enzyme inhibitors, losartan offers the ability to inhibit the
effects of Ang II activity specifically at the level of the receptor [9].
The purpose of this study was to assess the effects of chronic
blockade of the RAS, initiated at the time of clipping, on blood
pressure, renal hemodynamic and clearance function and glomer-
ular histology of clipped and nonclipped kidneys of 2-K 1-C HT
rats. We compared the effects of chronic blockade of the RAS
achieved with enalapril or losartan to no treatment in identically
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prepared animals. Further, to explore the possible role of Ang II
in the development of albuminuria in RVI-I, we compared the
effects of three weeks of treatment with the converting enzyme
inhibitor or the receptor antagonist on 24-hour urinary albumin
excretion and on albumin excretion for each kidney in 2-K 1-C
HT.
Methods
Animals and protocol
2-K 1-C Goldblatt hypertension was produced by placing a
silver clip (0.2 mm internal diameter) on the right renal artery of
male Wistar rats weighing 80 to 120 g (Charles River, Wilmington,
MA, USA) under pentobarbital anesthesia (50 mg/kg i,p,). All
animals were fed standard rat chow (Wayne Rodent Blox, Teklad,
Madison, WI, USA) containing 0.31% sodium and were allowed
tap water ad libitum. Rats were randomly divided into three
groups. Group one rats received losartan 20 mg/kg/day (N = 7),
and group two animals received enalapril 20 mg/kg/day (N 8).
Treatments were delivered in the drinking water from one day
after clipping and continued until clearance studies were con-
ducted. Nine additional clipped rats remained untreated to serve
as controls (group 3). The dose of losartan was determined from
a preliminary study as the dose equipotent to enalapril 20
mg/kg/day in preventing the development of hypertension in this
model. Systolic blood pressure (SBP) was measured in awake rats
by the tail-cuff method prior to clipping and twice weekly during
the study period. All animals were placed in metabolic cages 18 to
24 days after clipping and two 24-hour urine samples were
collected for the measurement of urinary albumin excretion.
Renal flinction
Animals were anesthetized with pentobarbital (50 mg/kg i.p.) 21
to 27 days after clipping and placed on a thermostatically con-
trolled, heated micropuncture table. The rats were then surgically
prepared for clearance study. After tracheotomy, three polyeth-
ylene catheters were inserted into a jugular vein for infusion of:
10% polyfructosan (mutest, Laevosan-Gesellschaft, Linz, Aus-
tria) and 2% para-aminohippurate (PAH; Merck Sharp &
Dohme, West Point, PA, USA) in 0.9% NaCI, and for the
supplemental administration of anesthetic. The total infusion rate
was 1.8 ml/hr during surgery. The left femoral artery was cannu-
lated for the direct blood pressure measurement and collection of
blood samples. Blood pressure was measured continuously with a
Statham pressure transducer, and recorded on a polygraph (Grass
Instrument Co., Quincy, MA, USA). The left kidney was exposed
through a flank incision and the left ureter was cannulated
proximally and ligated distal to the cannula. The urinary bladder
was cannulated through an abdominal incision for collection of
urine samples from the right kidney. Following completion of
surgery, the polyfructosan and PAH solution and the 0.9% NaCl
were administered as priming volumes of 0.6 ml each, followed by
an infusion rate of 0.6 mI/hr (total infusion rate 1.2 ml/hr). One
hour was allowed to achieve steady state conditions and then two
or three timed (30 mm) urine collections were obtained. Blood
samples for measurement of plasma polyfructosan and PAH
concentrations and hematocrit were taken before and after each
urine collection period. Following clearance periods, bolus injec-
tions of 25 and 50 ng Ang I were administered intravenously in six
to seven rats from each group. Increments in mean arterial
pressure (MAP) were used as an index of the magnitude of
inhibition of Ang II formation by enalapril or blockade of Ang II
receptors by losartan. At the end of the experiment, placement of
the clip was confirmed and both kidneys were removed, blotted
gently and weighed.
Renal histology
An additional three groups of clipped rats (untreated or treated
with losartan or enalapril) were prepared for histological study.
Three weeks after clipping, tail-cuff pressures were measured.
Rats were then anesthetized, placed on a thermostatically-con-
trolled heated table and the left femoral artery was cannulated for
the direct measurement of MAP. Following stabilization, MAP
was obtained over a 10 minute period. The aorta was then
cannulated above the illiac bifurcation and clamped distal to the
diaphragm. Small incisions were quickly made in both renal veins;
the kidneys were immediately perfused in situ, initially with 0.9%
NaCI and then with Bouin's fixative, at pressures approximating
renal perfusion pressure. The kidneys were removed and further
immersion fixed, routinely processed, paraffin embedded, cut in 5
j.m sections and stained with hematoxylin and eosin and PAS.
Histological evaluation was performed with the examiner (EL)
blinded as to source of the kidney. Changes in glomerular
architecture were quantitatively evaluated in 10 to 40 randomly
chosen cortical glomeruli in each kidney in which the sectioning
plane had passed through the hilum and included the efferent
and/or afferent arteriole. In these properly oriented glomeruli two
measurements were made at a magnification of 400x. First, the
distance from the hilar vessels to the edge of the glomerulus
nearest the urinary pole was measured. Second, the greatest
glomerular width was measured perpendicular to the first mea-
surement. These two values in microns were multiplied for each
glomerulus to give the glomerular size index. Mesangial matrix
expansion was evaluated using the criteria of Raij, Azar and
Keane [111. Briefly, expansion was assessed by the accumulation
of increased amounts of finely granular periodic acid-Schiff (PAS)
positive matrix in the glomerular mesangium. Glomeruli were
scored semiquantitatively to evaluate the degree of damage on an
arbitrary scale from 0 to 4 according to the percentage of
glomerular involvement. Thus 25% involvement of the glomeru-
lus was a score of I while 75% involvement represented a score of
3. In addition, the presence of distinct, spherical PAS positive
staining deposits was noted.
Analytical procedures
Urine samples were collected under oil in preweighed contain-
ers and urine volumes were determined gravimetrically. Polyfruc-
tosan and PAH concentrations in plasma and urine were mea-
sured by modified semimicro, colorimetric techniques [12, 131.
Glomerular filtration rate (GFR) was determined from the clear-
ance of polyfructosan. Renal plasma flow (RPF) was estimated
from PAH clearance adjusted for an average measured extraction
ratio of 0.83. Renal blood flow (RBF) filtration fraction (FF) and
renal vascular resistance (RVR) were then calculated using
standard formulae. Plasma and urine sodium and potassium
concentrations were measured with flame photometry. Urinary
albumin concentration was measured with an immunoelectro-
phoresis technique [14] using a sensitive and specific rabbit
antiserum to rat serum albumin.
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Three weeks post-clip
Preclip
body wt Kidney weight gGroup N g Body wt g Nonclip Clip
MAP
mm Hg
Control 9 102 4 287 10 1.49 0.05" 1.16 0.06
Losartan 7 99 7 288 9 1.70 0.10" 1.11 0.03
Enalapril 8 100 4 254 4"" 1.48 0.06" 0.97 0.04"
171 6
109 60
94 4"
Data are expressed as mean SEM.
P < 0.01 compared with control group
"P < 0.01 compared with losartan group
"P < 0.01 compared with clipped kidney
Statistical analysis
Data obtaihed from each experimental group are expressed as
the mean SEM. Tail-cuff SBP data for each treatment group
were analyzed by analysis of variance (ANOVA) for repeated
measures. Data obtained for SBP, MAP and clearance parameters
were analyzed using one-way ANOVA. Multiple comparisons of
the means were subsequently analyzed by BonferronilDunn or
Student-Newman-Keuls methods, where appropriate. Data with
unequal variances were analyzed using non-parametric Kruskal-
Wallis one-way ANOVA, and comparisons between the means
were subsequently analyzed by Mann-Whitney test with the
Bonferroni modification applied to determine significance. Dif-
ferences in function between clipped and nonclipped kidney for
each treatment group were analyzed by Student's unpaired t-tests.
Data were analyzed using Statview and SuperAnova (Abacus
Concepts, Berkley, CA, USA) and significance was accepted as
P < 0.05.
Results
Body weight, kidney weight, blood pressure and albumin excretion
in conscious rats
Prior to clipping there were no significant differences in body
weight among the three groups (Table 1). Three weeks after
clipping, the body wt of the control, losartan and enalapril groups
were 287 10, 288 9 and 254 4 g, respectively. The body
weight of the enalapril group was significantly lower than either
the control or losartan groups (P < 0.01). Despite the slightly
lower growth rate, the rats in the enalapril group remained
healthy. In all groups, the weight of the left, nonclipped kidney
was greater than that of the clipped kidney (P < 0.001). The
weight of the right, clipped kidney for the enalapril group was
significantly lower than that for the control group (P < 0.05), but
was not different when corrected for body wt.
Prior to clipping, systolic blood pressure was not different
anlong the three groups. In the control group of 2-K 1-C
hypertensive rats, SBP increased from a preclip value of 105 2
mm Hg to 188 11 mm Hg at three weeks (Fig. 1). No significant
increases in SBP were found during the thiee weeks following
clipping in either the losartan or enalapril groups. On day 21,
SBPs for the losartan and enalapril groups were 116 6 mm Hg
and 113 2 mm Hg, respectively. SBPs for the two treated groups
did not differ significantly at any time during the three weeks.
Three weeks after clipping, urinary albumin excretion (UaIhV)
was 17.8 6.8 mg/day in the awake hypertensive control group
(Fig. 2). Both the losartan and enalapril groups had significantly
Fig. 1. Systolic blood pressure (SBP) measured by the tail cuff method in
conscious rats prior to and following the placement of a renal arrezy clip. SBP
of untreated control rats was increased from 7 days ostclip (——--.).
Chronic treatment with either losartan (———) or enalapril (—A—)
prevented the increase in SBP induced by renal artery clipping through
three weeks. § P< 0.01 compared with preclip, ** P < 0.01 compared with
control group (comparisons tested by either contrasts or by Bonferroni/
Dunn method generated from the appropriate one-way repeated mea-
sures ANOVA).
lower UaibV compared to the control animals (1.7 0.5 mg/day,
P < 0.01 and 0.7 0.1 mg/day, P < 0.01, respectively). Although
the average UalbV tended to be lower in the enalapril group than
for the losartan group, this difference did not achieve statistical
significance.
Acute clearance studies—Blood pressure, renal function and renal
hemodynamic changes
Mean arterial pressure (MAP) measured directly in anesthe-
tized rats during the clearance studies was 171 6 mm Hg for the
untreated, control group. In contrast, MAP for both the losartan
and enalapril treated groups was significantly lower (109 6 mm
Hg, P < 0.001, and 94 4 mm Hg, P < 0.001, respectively). There
was no significant difference in MAP between the two treated
groups.
The average values for GFR were not different between the
nonclipped and clipped kidneys of the untreated group. In
contrast, GFR was significantly higher in nonclipped compared to
clipped kidneys for both treated groups (Fig. 3). The average
values for GFR of the nonclipped kidney were significantly higher
(P < 0.01) for the losartan (1.57 0.13 ml/min) and the enalapril
groups (1.39 0.07 mI/mm) than for the untreated group (1.02
0.07 mI/mm). Interestingly, despite the three weeks of normalized
systemic blood pressure by either inhibition of Ang II formation
or blockade of Ang II receptors, mean values of GFR for the
clipped kidneys of both treated groups were not different from
that determined for the corresponding kidneys of the control
group. This effect of treatment to increase GFR of the nonclipped
Table 1. Body weight, kidney weight and mean arterial pressure (MAP) §
§
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imamura et a!: Chronic ANG Ii blockade in 2-K 1-C hypertension 1397
60
- 50'
40'
30
E
20-
10
Control Losartan Enalapril
(N=8) (N=7) (N=8)
Fig. 2. Urinary albumin excretion rate of conscious rats three weeks after
renal artery clipping. 2-K 1-C rats treated chronically with either losartan or
enalapril had markedly attenuated albuminuria compared with untreated
hypertensive rats, ** P < 0.01 compared with control group (comparisons
using the Mann-Whitney test with the Bonferroni modification).
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Fig. 3. Glomerular filtration rate, effective renal plasma flow and filtration
fraction of the nonclipped and clipped kidneys from untreated hypertensive
and treated 2-K 1-C rats. The GFR of the nonclipped kidneys from the
losartan () orenalapril () groups was increased compared to that of the
control (•) group. The RPF of the nonclipped kidneys from the losartan
group was increased compared to that of the control group. There are no
differences in the hemodynamics of the clipped kidney among the three
groups. **P < 0.01 compared with control group; if P < 0.01 compared
with clipped kidney from the same group (comparisons tested by Student-
Newman-Keuls method generated from one way ANOVA).
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kidney as well as maintain the GFR of the clipped kidney was also
observed when the values for GFR were normalized for differ-
ences in kidney weight.
Renal hemodynamic data obtained from the three groups are
shown in Figures 3 and 4. The average values for RPF were not
different between the nonclipped and clipped kidneys of the
untreated group. In contrast, mean RPF values were significantly
higher for the nonclipped kidneys compared to clipped kidneys
for both treated groups (Fig. 3). RPF for the nonclipped kidney
from the losartan group was higher (P < 0.01) than that of the
nonclipped kidney from the control group. Again, mean values of
RPF for the clipped kidneys of both treated groups were not
different from that determined for the corresponding kidneys of
the control group (3.38 0.47, 3,27 0.39 and 2.56 0.45
ml/min for the untreated, losartan and enalapril groups, respec-
tively). Total RPF did not differ among the three groups. Since
nonclipped and clipped kidney weights for the groups differed,
RPF data were also examined factored for kidney wt. The mean
plasma flow for nonclipped kidneys was significantly larger (P <
0.05) in both the losartan and enalapril groups (3.79 0.36 and
3.60 0.34 ml/min/g kidney wt, respectively) compared to that for
the control group (2.58 0.30 ml/min/g kidney wt). When
factored for kidney wt, mean values of RPF for the clipped
kidneys of both treated groups were not different from that
determined for the corresponding kidneys of the control group.
There were no differences in FF between nonclipped or clipped
kidneys among the groups (Fig. 3).
Data for RBF and RVR are shown in Figure 4. For both treated
groups, RBF was higher in the nonclipped than the clipped
kidneys. The mean RBF of nonclipped kidneys was higher in the
losartan group than in the control group (12.12 1.18 and 7.72
0.81 ml/min, respectively, P < 0.01). The mean values of RBF for
the clipped kidneys did not differ among the three groups. When
factored for kidney wt, no significant differences were found for
RBF for nonclipped kidneys between the losartan and control
groups, and no difference was found between nonclipped and
clipped kidney RBF for either the losartan or enalapril groups. In
both losartan and enalapril groups, nonclipped kidney RVR was
significantly lower than in the control group (P < 0.01).
Values for absolute Na excretion from the nonclipped and
clipped kidneys of the control group were 155 60 and 32 13
nmol/min (P < 0.05), respectively, values not different from those
observed for the corresponding kidneys for either treatment
group. Although absolute Na excretion (UNaV) for nonclipped
k3°
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Fig. 4. Estimated renal blood flow and renal vascular resistance of the
nonclipped and clipped kidneys from untreated and treated 2-K 1-C rats.
Losartan (Li) or enalapril () induced a marked vasodilation of the
nonclipped compared with the nonclipped kidneys of the control (U) rats.
This vasodilation was associated with an elevated nonclipped kidney blood
flow in the losartan group or the maintenance of blood flow in the
nonclipped kidney of rats treated with enalapril. Clipped kidney vascular
resistance was not altered by treatment. P < 0.01 compared with
control group; t P < 0.05; if P < 0.01 compared with clipped kidney from
the same group (comparisons tested by Student-Newman-Keuls method
generated from one way ANOVA).
or clipped kidneys was not changed in the losartan or enalapril
treated groups, the fractional Na excretion from the nonclipped
kidney was lower in both the losartan or enalapril treated groups
(0.07 0.02 and 0.07 0.02%, respectively compared to 0.12
0.05 for the control group, P < 0.05). Treatment with losartan or
enalapril was associated with lower UKV for the clipped kidney
(430 100 or 444 110 nmol/min, respectively, vs. 820 150 for
the control group, P < 0.05), but UKV by the nonclipped kidney
was unaffected. Fractional excretion of K did not differ among
the groups (control group, nonclipped kidney 30 6% and
clipped kidney 24 4%; losartan group 25 4 and 15 2%, and
enalapril group 30 3 and 18 2%, respectively).
Urinary albumin excretion rates (Ua!bV), obtained from the
acute clearance experiments during anesthesia, are shown in
Figure 5. Nonclipped kidney UalhV was significantly greater than
that from the clipped kidney in all groups: 15.1 3.1 g/min
versus 3.1 1.1 xWmin in control group, P < 0.01, 5.3 1,0
g/min versus 0.3 0.1 xgImin in losartan group, P < 0.001 and
3.3 0,8 xg/min versus 0.7 0.3 gImin in enalapril group, P <
0.01. UahV from both nonclipped and clipped kidneys was
significantly (P < 0.01) less for the losartan and enalapril groups
compared to the corresponding kidneys of the control group.
Pressor response to angiotensin I injection
The increments in MAP following bolus injection of 25 and 50
ng Ang I were attenuated by approximately 75% in both losartan
and enalapril groups compared to the control group. The ZMAP
responses to either dose of Ang I were not different between the
losartan and enalapril groups. The LMAP for the untreated group
in response to 25 ng Ang I was 20 3 mm Hg compared to 5
2 mm Hg for both the enalapril and losartan groups.
Renal histology
The three additional groups subjected to histological study
exhibited SBPs and MAPs which were not different from the
groups subjected to the study of renal function of each kidney.
The SBPs and MAPs of the rats for histological study were 186
8 and 177 9, 125 12 and 118 3, 121 4 and 108 2 mm
Hg for the control, losartan and enalapril groups, respectively.
Indices of glomerular size and mesangial expansion for the
nonclipped or clipped kidneys from each of the groups are
presented in Table 2. For the untreated group, there were no
significant differences in the indices of glomerular size or mesang-
ial expansion between the clipped and nonclipped kidneys. In
contrast, for both the treated groups, the indices of glomerular
size or mesangial expansion were significantly (P < 0.01) lower for
clipped compared to nonclipped kidneys. The indices of glomer-
War size and mesangial expansion determined for the nonclipped
kidneys of the losartan or the enalapril treated groups did not
differ significantly from the values determined for the untreated
group. The indices of glomerular size and mesangial expansion for
the clipped kidneys from the losartan treated group were signifi-
cantly lower compared to those determined for corresponding
kidneys of the untreated rats. There was a trend for the indices
from the clipped kidneys from the enalapril treated group to be
lower compared to the untreated group, but the differences did
not achieve statistical significance.
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Fig. 5. Urinaiy albumin excretion (UIhV p.glmin) of nonclipped and
clipped kidneys from anesthetized 2-K 1-C rats at the time of acute clearance
study (3 weeks postclip). Losartan (LI) and enalapril () induced a
significant reduction in UaIhV from both kidneys. Symbol (U) is control.
was markedly elevated in nonclipped kidneys compared to the
clipped kidneys in all groups. Thus the reduction in UaIbV observed in the
treated groups was principally due to a reduction in albumin excretion
from the nonclipped kidney. * P < 0.05 compared with control group;
<0.01 compared with control group; if P < 0.01 compared with clipped
kidney from the same group (Comparisons tested by Student-Newman-
Keuls method generated from one way ANOVA).
Nonclipped Clipped
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A. Olomerular size index
GIomerular size index (jM X 102)
Kidney Control Losartan Enalapril
Clipped 90.1 4.5
(30/3)
Nonclipped 96.6 4.0
(30/3)
68.1 3.0"
(30/3)
100.5 4.0"
(30/3)
80.9 4.2
(30/3)
107.6 5.2a
(30/3)
B. Mesangial expansion index
Mesangial expansion index
Kidney Control Losartan Enalapril
Clipped 1.1 0.1 0.7 0,1b 0.9 0.1
(120/6) (119/6) (120/6)
Nonclipped 1.3 0.1
(120/6)
1.4 0.1"
(119/6)
1.5 OP
(120/6)
In addition to the mesangial expansion (which was manifested
as increases in finely granular PAS-positive matrix), we observed
discrete PAS-staining spherical deposits in many glomeruli from
nonclipped kidneys of untreated control rats (Fig. 6). These
discrete PAS-staining spherical deposits were usually large when
located in the hilar regions but tended to be smaller in the
perpheral capillary ioops. The deposits were not necessarily
coincident with mesangial expansion. Losartan treatment signifi-
cantly reduced, and enalapril treatment abolished, the presence of
the spherical deposits without significantly affecting mesangial
expansion. In contrast to the nonclipped kidneys, glomeruli from
the clipped kidneys did not show any evidence of discrete PAS-
staining deposits, irrespective of the group to which the rats
belonged.
Discussion
This study assessed the effects of angiotensin receptor blockade
or ACE inhibition on blood pressure, renal function, albumin
excretion and renal histology in both clipped and nonclipped
kidneys of two-kidney, one-clip hypertensive rats. As reported
previously, chronic administration of ACET, introduced soon after
clipping, prevents the development of systemic hypertension in
2-K 1-C hypertensive rats [15, 16]. Our new finding, that similar
antihypertensive effects were obtained with losartan, indicates
that AT1 receptor-mediated effects of Ang II are critical to the
initial development of hypertension, and implies that ACEI
prevents the development of elevated blood pressure chiefly by
inhibiting conversion of Ang I to Ang II. Consequently, these
observations do not support a major role for kinin potentiation in
the antihypertensive effects of ACEI in this model. Whereas the
measurements of SBP obtained in awake rats from the enalapril
and losartan groups were almost identical, under anesthesia, MAP
in the enalapril group fell to somewhat lower levels than in the
losartan-treated rats. The growth rate in the enalapril group also
appeared slightly lower than that in the losartan group. Whether
either or both of these slight inter-group differences reflect
inequality in the extent of RAS inhibition achieved, or class-
associated differences between the agents, is unclear. In either
case, the differences are small and unlikely to be important to the
main aspects of this study.
Treatment, either with enalapril or losartan, while preventing
any significant rise in blood pressure, was associated with aug-
mentation of both GFR and RPF of the nonclipped kidney when
compared to the corresponding kidney in untreated rats, This
finding contrasts with the recent report of decreased GFR of
nonclipped kidneys following chronic treatment with enalapril in
rats with established renovascular hypertension [17]. Augmenta-
tion of renal hemodynamic function in the nonclipped kidney
may, in part, be due to inhibition of the effects of Ang II within the
kidney which, in addition to the effects of Ang II on systemic
vascular resistance, are thought to contribute to the generation of
hypertension in 2-K 1-C rats [reviewed in 1]. Measurements of
components of the RAS in the nonclipped kidney reveal that,
whereas renin levels are markedly suppressed [8], Ang II levels
appear to be significantly elevated [18]. Altered physiological
behavior in the nonclipped kidney, such as blunting of autoregu-
lation and pressure-natriuresis responses, may result from specific
actions of Ang II. Acute inhibition of the RAS in 2-K 1-C rats,
either by ACEI or Ang II receptor antagonist administration,
results in significant increases in RBF, GFR and renal excretory
function in the nonclipped kidney despite profound contempora-
neous decreases in blood pressure [4, 8, 19]. These findings are
consistent with inhibition of known acute intrarenal effects of Ang
II, for example, to increase renal vascular resistances at both pre-
and post-glomerular segments, to decrease K, and to increase
tubular fluid reabsorption [20, 21]. Our present findings of
increased RPF and GFR in nonclipped kidneys of the treated
groups suggest that the effects of chronic inhibition of the RAS
are sustained and, to some degree, parallel the effects of acute
inhibition. In contrast to the increased fractional Na excretion
from the nonclipped kidney following acute inhibition of the RAS,
chronic treatment with losartan or enalapril in the present study
resulted in a lower FENU* from the nonclipped kidney. The lower
FENa* for the nonclipped kidneys of the losartan and enalapril
treated groups may reflect a tubular mechanism to chronically
regulate urinary Na4 excretion in the face of the augmented GFR
and increased filtered load of Na.
In the present study two distinct forms of PAS-positive material
were observed in glomeruli from nonclipped kidneys of untreated
control 2-K 1-C hypertensive rats: (i) diffuse, finely-granular
staining identified as mesangial matrix expansion and (ii) discrete
more densely staining spherical deposits representing deposition
of hyalin. Although both of these forms of PAS-positive material
may represent early glomerular damage, the deposition of hyalin
probably represents an early manifestation of glomeruloscierosis
[221. Losartan or enalapril greatly reduced the distinct glomerular
hyalin deposits and prevented the development of proteinuria in
the nonclipped kidney. These findings suggest that blockade of the
RAS in 2-K 1-C rats either prevents or delays the evolution of
glomerular changes associated with the development of sclerotic
lesions. Although our protocol did not include untreated normo-
tensive rats for comparison, approximately 38% of the glomeruli
from nonclipped kidneys of untreated 2-K 1-C hypertensive rats
Table 2. Histological indices of glomeruli from untreated 2-K 1-C
hypertensive rats, and from 2-K 1-C rats chronically treated with
losartan or enalapril
Kidneys were perfused-fixed three weeks after renal artery clipping.
Data are presented as mean SEM.
a P < 0.01 compared with clipped kidney from same group
h P < 0.05 compared with clipped kidney of control group
"P < 0.01 compared with clipped kidney of control group
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Fig. 6. Light micrographs of paraffin-embedded kidney sections stained with PAS. Glomeruli from (a) clipped kidney of untreated rats show normal
appearing capillary loops and mesangium, (b) nonclipped kidney of untreated rats show distinct circular-shaped mesangial deposits of varying sizes.
Glomerulus (c) from nonclipped kidney of enalapril treated rat shows extensive staining of the mesangium including the hilar region (mesangial
expansion grade = 3). No distinct spherical deposits were observed in glomeruli from nonclipped kidneys of enalapril treated rats. Magnification 1300x
for all panels.
had moderate to severe accumulation (50% or greater involve-
ment of the glomerulus) of diffuse PAS-staining material, suggest-
ing that the development phase of this model is accompanied by
increased elaboration of mesangial matrix. Interestingly, a similar
degree of expansion of mesangial matrix was observed in glomer-
uli from the nonclipped kidneys of rats in both treatment groups.
Expansion of mesangial matrix may he a forerunner of glomerular
damage induced by glomerular hypertension [22] or by the effects
of angiotensin II. However, in the present study, expansion of
mesangial matrix occurred under conditions of significant RAS
blockade and the complete abrogation of hypertension. These
findings suggest that mesangial matrix expansion, without the
coexistence of hypertension and/or angiotensin II, does not ap-
pear to be detrimental to glomerular functional integrity during
the early phase following renal artery clipping.
In the present study, chronic ACEI was not associated with
significant deleterious effects on clipped kidney function. This
finding contrasts with reports of severe impairment of clipped
kidney function in response to acute administration of ACEI to
2-K 1-C hypertensive rats [4, 6—8]. Before drawing conclusions
regarding this apparent discrepancy, it should be emphasized that
the acute or chronic effects of RAS inhibition have previously only
been studied after hypertension was established in this model.
Acute reductions in blood pressure from hypertensive levels result
in impaired RBF, reduced GFR and decreased excretory function
of the clipped kidney. In some settings, where RAS activity is
presumably augmented by prior volume depletion, the effects of
acute ACEI may be so severe that acute renal failure results. Such
decreases in post-stenotic kidney function observed after RAS
inhibition have been attributed either to perfusion pressure being
decreased to levels below the autoregulatory threshold as a result
of profound decreases of systemic BP, or to loss of specific
intrarenal effects of Ang II, such as, specific maintenance of
post-glomerular arteriolar tone. Our data clearly show that when
RAS inhibition is introduced before the development of hyper-
tension, renal function in the post-stenotic kidney is comparatively
well maintained. This observation is even more remarkable when
the conditions under which the clearance data were obtained are
considered. Under anesthesia, MAP was measured at levels close
to (losartan group) or frankly below (enalapril group) the usual
lower limit of GFR autoregulation. From published data [5, 23]
and our own observations [Mackenzie and Ploth, unpublished
observations], it is reasonable to assume that during anesthesia
post-stenotic perfusion falls well below the usual lower limit of
autoregulation in both the enalapril and losartan treated groups.
The fact that function of the post-stenotic kidney is well main-
tained under the conditions of this study has two important
implications: (1) renal homeostatic mechanisms for maintaining
GFR and RPF may be more effective when adapting to gradual
rather than sudden changes in systemic perfusion pressure, and
(2) an intact RAS does not appear to be essential to the long-term
maintenance of GFR in the clipped kidney. In particular, these
observations do not support a role for Ang Il-induced preferential
efferent arteriolar constriction in the maintenance of GFR.
The clipped kidneys from the untreated hypertensive rats
appeared free of structural damage to glomeruli. These observa-
tions are in accordance with the findings of Wilson and Byrom
[summarized in 24] that the clipped kidneys of 2-K 1-C hyperten-
sive rats do not show evidence of glomerular lesions. Interestingly,
in the present study, the clipped kidneys from rats treated with
losartan or enalapril did not show evidence of ischemic glomeru-
lar damage that would be expected to follow inadequate post-
stenotic perfusion. These findings are at variance with earlier
reports that chronic administration of ACEI to 2-K 1-C hyperten-
sive rats is associated with fibrosis and atrophy of the clipped
kidney, amounting to "pharmacologic nephrectomy" in one study
[7]. Our data on the function and structure of the clipped kidney
may be interpreted as supporting the notion that, whereas sudden
introduction of RAS inhibition may be associated with acute and
possibly permanent impairment in GFR and RPF, chronic admin-
istration or possibly gradual administration of ACEI, avoiding
initial abrupt decreases in blood pressure, is less likely to have
adverse effects on the function and structure of the post-stenotic
kidney. Further, a recent report suggests that the phenomenon of
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acute impairment in renal function with ACEI may be avoided if
the agent is introduced gradually, in a step-wise fashion [25].
Mild to severe proteinuria has been observed with renovascular
hypertension in humans [26, 27] and rats [28] and the magnitude
of proteinuria can be reduced by treatment with ACEI in man [27,
29]. However, treatment with enalapril did not reduce albumin-
uria in rats with RVH when it was initiated six weeks post-clipping
[28], suggesting that in this model proteinuria may represent fixed
structural damage of the glomerular barrier rather than a revers-
ible or functional abnormality. One of the goals of the present
study was to determine whether ACEI or Ang II receptor
blockade would prevent the development of albuminuria if started
prior to the onset of hypertension. We found that enalapril or
losartan completely attenuated the albuminuria observed three
weeks after clipping in the untreated rats. In both treated groups,
UaIbV was similar to that measured in normal rats of comparable
size in our laboratory (0.5 to 1.0 mg/day). The anti-albuminuric
response to losartan and enalapril parallel those reported in other
models of chronic progressive renal disease [30—32].
An additional original observation in the present study is the
effect of ACEI or losartan on the albumin excretion from the
individual nonclipped and clipped kidneys. Although the differ-
ence in albumin excretion rate between the control and either of
the two treated groups was decreased during anesthesia, signifi-
cant differences in albumin excretion between treatment and
control groups remained. In the untreated hypertensive rats, the
albumin excretion rate from the nonclipped kidney exposed to the
hypertensive perfusion pressure was 5- to 10-fold greater than that
from the clipped kidney, suggesting that the nonclipped kidney is
the principal source of the albuminuria in 2-K 1-C hypertensive
rats. The attenuation of albuminuria by losartan or enalapril
treatment indicated reduction in albumin excretion from both the
nonclipped and clipped kidneys, although the absolute decrease
was greater from the nonclipped kidney. Further, the substantially
different absolute albumin excretion rates between the nonclipped
and clipped kidneys was maintained in the enalapril and losartan
groups. It has been suggested that Ang II induces the increased
protein excretion observed in other models of renal disease [33,
34]. The present finding that there is a marked difference in UalbV
between the nonclipped and clipped kidneys during inhibition of
ACE or blockade of Ang II would suggest that the reduction in
albumin excretion was not due to the inhibition of the direct
effects of Ang II on glomerular protein permeability, but may
reflect abrogation of systemic hypertension or other effects.
In summary, we observed similar efficacy of the antihyperten-
sive effect of chronic CEI and angiotensin receptor blockade in
2-K 1-C hypertensive rats. Following three weeks of maintained
normal systemic BP in the treated groups, renal function of the
nonclipped kidney was generally increased; the function of the
clipped kidney was unchanged compared to the respective kidneys
of untreated, hypertensive control animals. While both treatment
protocols reduced albumin excretion from nonclipped and clipped
kidneys and appeared to prevent the development of early signs of
glomerulosclerosis in nonclipped kidneys, neither treatment was
associated with adverse effects on clipped kidney structure as
evidenced by histologic evaluation. These observations support
the concept that, despite normalized blood pressure resulting
from prolonged blockade of the RAS, function and histology of
the clipped kidney are preserved with impressive efficiency.
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